Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dabrafenib/Trametinib Combo Wins EU Approval for BRAF+ NSCLC

April 3rd 2017

The European Union (EU) approved the combination of dabrafenib and trametinib for patients with BRAF V600-positive advanced or metastatic non–small cell lung cancer.

Five-Year Survival Rate an Impressive 16% With Nivolumab in Advanced NSCLC

April 3rd 2017

Long-term survival in patients with metastatic non–small cell lung cancer who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of these patients surviving after 5 years, equivalent to about 4 times what would be expected with chemotherapy.

Anticipated Osimertinib Data Could Transform Frontline NSCLC Treatment

March 31st 2017

Jamie E. Chaft, MD, discusses the effectiveness of osimertinib (Tagrisso) and what the future holds for patients with EGFR-mutant non-small cell lung cancer.

FDA Grants Full Approval to Osimertinib for T790M+ NSCLC

March 31st 2017

The FDA has granted a regular approval to osimertinib as a treatment for patients with metastatic EGFR T790M mutation-positive non–small cell lung cancer following prior treatment with an EGFR TKI, based on progression-free survival findings from the phase III AURA3 trial.

Dr. Swanson on Treating Multifocal Lung Cancer

March 31st 2017

Scott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses treating multifocal lung cancer.

Novel Agents Continue to Make Mark in Lung Cancer

March 30th 2017

Mark B. Stoopler, MD, discusses ongoing developments in immunotherapy and his vision for the future of non-small cell lung cancer treatment.

Efforts Continue to Introduce Immunotherapy Into Earlier NSCLC Settings

March 28th 2017

Daniel Costin, MD, shares insight on understanding the deeper biology of the immune system, the emerging research with immunotherapy, and the importance of managing associated adverse events.

Dr. Drilon on Immunotherapy in Lung Cancer

March 28th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with lung cancer.

Dr. Papadimitrakopoulou on Immunotherapy Combinations in Lung Cancer

March 28th 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses trials investigating combinations of immunotherapy regimens in lung cancer.

Expert Tackles Efficacy of PD-L1 Testing for NSCLC in 2017

March 28th 2017

Daniel B. Costa, MD, PhD, discusses biomarker testing in non-small cell lung cancer and the necessary next steps for PD-L1 testing.

Dr. Spigel on Pembrolizumab/Chemo Combo in First-Line NSCLC

March 27th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the results of cohort G from the KEYNOTE-021 trial, which explored pembrolizumab (Keytruda) combined with pemetrexed/carboplatin as a frontline treatment for patients with nonsquamous non–small cell lung cancer (NSCLC).

Dr. Jackman on Overcoming Resistance to EGFR Inhibitors in Lung Cancer

March 27th 2017

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

Osimertinib Approved in China for EGFR T790M+ NSCLC

March 27th 2017

The China Food and Drug Administration has approved osimertinib for the treatment of patients with locally-advanced or metastatic EGFR T790M-positive non-small cell lung cancer with progression following treatment with an EGFR tyrosine kinase inhibitor.

Expert Provides Perspective on Immunotherapy Advances in Lung Cancer

March 27th 2017

Jared Weiss, MD, offers his expert insight into the actual impact of the immunotherapy advances in lung cancer.

Dr. Husain on the Future of Monitoring T790M in Lung Cancer

March 24th 2017

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).

Dr. Evans on Challenges of Immunotherapy in Lung Cancer

March 24th 2017

Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Expert Discusses Next Steps With Immunotherapy, Targeted Agents in NSCLC

March 11th 2017

Vassiliki A. Papadimitrakopoulou, MD, discusses recent developments with immunotherapy in non-small cell lung cancer and the continued significance of EGFR and ALK inhibitors in the field.

Dr. Levine on Palliative Care for NSCLC

March 7th 2017

Stacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, University of Chicago Medicine, discusses the benefits of palliative care for patients with non–small cell lung cancer (NSCLC).

Dr. Socinski on Milestone of Immunotherapy in Lung Cancer

March 6th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses the type of milestone that immunotherapy has had on the field of lung cancer.

Dr. Sabari on Future of Immunotherapy in SCLC

March 3rd 2017

Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses the future that immunotherapy has in the field of small cell lung cancer (SCLC).